Market news

Legend Biotech (NASDAQ:LEGN) presents a compelling equity thesis centered on transforming breakthrough oncology innovation into a high-margin, cash-generative cell therapy franchise. Maintaining a fortress balance sheet anchored by approximately $965 million in cash, cash equivalents, and time deposits as of June 30, fortified by $212 million in net proceeds from a public offering of American […]

Ingrid Zhang, an accomplished global biopharmaceutical leader, joins Legend Biotech following a comprehensive Board-led search processBRIDGEWATER, N.J., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) ("Legend Biotech" or the "Company"), a global leader in cell therapy, today announced that its Board of Directors has appointed Ingrid Zhang as Chief Executive Officer, effective September 15, 2026. Ingrid Zhang succeeds Alan Bash, who has served as Interim Chief Execut

Legend Biotech (LEGN) drew fresh investor attention after announcing that interim CEO Alan Bash will speak at the Morgan Stanley Global Healthcare Conference on September 15, 2026. The company plans to highlight its CAR-T focus and commercial footprint during the event. Legend Biotech’s share price has been volatile, with a 13.91% 1 month share price return, followed by a 41.27% decline over 3 months and a 38.25% fall in 1 year total shareholder return. This suggests that long term momentum...

BRIDGEWATER N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that Alan Bash, interim Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference in New York, NY on Tuesday, September 15, 2026, at 2:35 p.m. ET. The live webcast will be available to investors and other interested parties by accessing the Investor Relations section of the Legend Bi

Detailed price information for Sagimet Biosciences Inc Series A (SGMT-Q) from The Globe and Mail including charting and trades.

Legend Biotech (LEGN) stock slides as Oppenheimer downgrades the company, citing its recent CEO exit, tougher competition, and weaker Carvykti sales. Read more here.

Legend Biotech (LEGN) is positioned to sustain profitability after achieving adjusted net income pro

Legend Biotech (LEGN) has an average rating of overweight and mean price target of $47.41, according

Detailed price information for Legend Biotech Corp ADR (LEGN-Q) from The Globe and Mail including charting and trades.

Legend Biotech achieves company-wide profitability with adjusted net income of $63 million, while advancing its promising in vivo CAR-T platform.

Legend Biotech just posted a quarter that flipped a key narrative for LEGN shareholders, but with a CEO transition underway and the stock still down sharply over the past year, the real question is whether this momentum can last.

Legend Biotech Corporation (NASDAQ:LEGN) shares gained 5. 5% in pre-market trading on Tuesday after the pharmaceutical company delivered better-than-expected second-quarter earnings and revenue, supported by continued growth in CARVYKTI sales.

Legend Biotech (NASDAQ:LEGN) reported second-quarter 2026 results marked by continued global growth for CARVYKTI and the company’s first quarter of company-wide profitability on both an IFRS and adjusted basis, management said during its earnings call. Interim Chief Executive Officer Alan Bash said

Motley Fool Press Release.

CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) net trade sales increased 50% versus second quarter of 2025 to approximately $657 millionExpanded CARVYKTI® availability to 348 global sites and 19 global markets with the launch of IrelandAchieved first clinical proof-of-concept for LB2501, an investigational in vivo CD19/CD20 dual‑targeting CAR-T therapy with 100% ORR and 83.3% CR at the higher dose level (DL2) in patients with relapsed or refractory B-cell non-Hodgkin lymphomaStrengthened balan

Ying Huang is now running K2 Therapeutics, which has licensed multiple prospects from China-based biotechs and is searching for more “high-potential” medicines.

Detailed price information for Legend Biotech Corp ADR (LEGN-Q) from The Globe and Mail including charting and trades.

Legend Biotech stock has seen a steep share price decline over the past few years, yet the latest valuation checks still point to shares screening as cheap on several measures. With fresh leadership changes and ongoing focus on its key CAR-T therapy, investors are weighing whether the recent weakness reflects business risk or a disconnect between price and fundamentals. Over the last 3 years, Legend Biotech shares have fallen 74.6%, which places recent valuation interest squarely on whether...

Legend Biotech’s CEO stepped down without warning, while Sarepta has appointed a biopharma veteran to take the company forward.

Legend Biotech, listed as NasdaqGS:LEGN, announced that CEO Ying Huang has stepped down. Alan Bash has been appointed as Interim CEO to lead the company through the transition. The leadership change comes at a time when Legend Biotech remains active in the competitive biotech sector. Legend Biotech focuses on developing and commercialising cell therapies, a field that attracts significant attention from both large pharmaceutical companies and specialist biotech investors. Leadership...

Legend Biotech recently announced that Ying Huang, Ph.D., has stepped down as Chief Executive Officer and Board member, effective July 24, 2026, with CARVYKTI business unit President Alan Bash appointed as Interim CEO and Dr. Huang staying on briefly as an advisor. This leadership reshuffle at the top of a company built around a single, high-profile CAR-T franchise raises important questions about continuity in execution, partnerships, and global expansion plans. Now we’ll examine how the...

BRIDGEWATER N.J., July 28, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 a.m. ET on Tuesday, August 11, 2026, to review second quarter 2026 financial results. During the conference call and accompanying webcast, senior management will provide an overview of quarterly financial performance. Investors and other interested parties may access the live audio webcast via this webli

Ying Huang, Ph.D., steps down as Chief Executive Officer and member of the Board of Directors; will remain as an advisor through August to support a smooth transitionAlan Bash, current President of the CARVYKTI Business Unit, appointed Interim Chief Executive OfficerBoard has initiated a comprehensive search process to identify a permanent successor BRIDGEWATER, N.J., July 27, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech” or the “Company”), a global leader

Legend said on Monday that Ying Huang stepped down as chief executive officer and board member effective July 24.

Health care sector oversold - buying opportunities in undervalued companies. RSI compares stock strength on up/down days, below 30 is oversold.